SummaryRMgm-5635
|
||||||||
*RMgm-5635| Successful modification | The parasite was generated by the genetic modification |
| The mutant contains the following genetic modification(s) | Gene mutation |
| Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 39576115 |
| MR4 number | |
| top of page | |
| Parent parasite used to introduce the genetic modification | |
| Rodent Malaria Parasite | P. berghei |
| Parent strain/line | P. berghei ANKA |
| Name parent line/clone | P. berghei ANKA 2.34 |
| Other information parent line | P. berghei ANKA 2.34 is a cloned, gametocyte producer line of the ANKA strain (PubMed: PMID: 15137943). |
| top of page | |
| The mutant parasite was generated by | |
| Name PI/Researcher | Liu Y, Zhu |
| Name Group/Department | Department of Immunology, College of Basic Medical Sciences |
| Name Institute | China Medical University |
| City | Shenyang |
| Country | China |
| top of page | |
| Name of the mutant parasite | |
| RMgm number | RMgm-5635 |
| Principal name | PbIMC1g(cKD) |
| Alternative name | |
| Standardized name | |
| Is the mutant parasite cloned after genetic modification | Yes |
| top of page | |
| Phenotype | |
| Asexual blood stage | See below 'Phenotype' and 'Additional Information' |
| Gametocyte/Gamete | See below 'Phenotype' and 'Additional Information' |
| Fertilization and ookinete | See below 'Phenotype' and 'Additional Information' |
| Oocyst | See below 'Phenotype' and 'Additional Information' |
| Sporozoite | See below 'Phenotype' and 'Additional Information' |
| Liver stage | Not tested |
| Additional remarks phenotype | Mutant/mutation Protein (function) PbIMC1g has an IMCp domain (aa 29–184) and a C-terminal region (aa 185–297). To assess which domain is needed for proper protein localization, we generated deletion constructs of PbIMC1g for episomal expression in wild-type P. berghei. Episomal expression of mCherry-tagged full-length PbIMC1g protein (FL) showed a similar localization pattern as PbIMC1g-HA. C-terminal deletion (ΔC) also localized the protein to the merozoite periphery, albeit diffused signals in the parasite cytoplasm were also visible. In contrast, deletion of the IMCp domain (ΔIMCp) completely abolished the peripheral localization pattern of the protein, indicating that he IMCp domain and, to a lesser extent, the C-terminal region of PbIMC1g protein are needed for its efficient IMC association. Protein palmitoylation, catalyzed by aspartate–histidine–histidine–cysteine (DHHC) palmitoyl acyltransferases in Plasmodium, plays a vital role in targeting proteins to the IMC and mediating protein-protein interactions. PbIMC1g has seven predicted palmitoylation sites at Cys residues 2, 10, 11, 233, 238, 255, and 296. To evaluate the importance of the predicted PbIMC1g palmitoylation sites in proper IMC targeting, we generated two PbIMC1g expression constructs in which the cysteine residues at N-terminus (C2, C10, and C11) and C-terminus (C233, C238, C255, and C296) were mutated to alanine, respectively. Disruption of the palmitoylation sites with both constructs resulted in noticeable mis-localization of the protein to the parasite cytoplasm in schizonts. However, the localization pattern of Palm-mutN and Palm-mutC at the ookinete stage was not altered.
|
Mutated: Mutant parasite with a mutated gene| top of page | |||||||||||||||||||||||||||
| Details of the target gene | |||||||||||||||||||||||||||
| Gene Model of Rodent Parasite | PbANKA_1240600 | ||||||||||||||||||||||||||
| Gene Model P. falciparum ortholog | PF3D7_0525800 | ||||||||||||||||||||||||||
| Gene product | inner membrane complex protein 1g | ||||||||||||||||||||||||||
| Gene product: Alternative name | IMC1g | ||||||||||||||||||||||||||
| top of page | |||||||||||||||||||||||||||
| Details of the genetic modification | |||||||||||||||||||||||||||
| Short description of the mutation | a fusion of IMC1g with HA-tagged mutant E. coli DHFR (cDDHA) | ||||||||||||||||||||||||||
| Inducable system used | No | ||||||||||||||||||||||||||
| Short description of the conditional mutagenesis | Not available | ||||||||||||||||||||||||||
| Additional remarks inducable system | |||||||||||||||||||||||||||
| Type of plasmid/construct | CRISPR/Cas9 construct: integration through double strand break repair | ||||||||||||||||||||||||||
| PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||||
| Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||||
| Plasmid/construct map | |||||||||||||||||||||||||||
| Plasmid/construct sequence | |||||||||||||||||||||||||||
| Restriction sites to linearize plasmid | |||||||||||||||||||||||||||
| Selectable marker used to select the mutant parasite | hdhfr/yfcu | ||||||||||||||||||||||||||
| Promoter of the selectable marker | eef1a | ||||||||||||||||||||||||||
| Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||||
| Selection (negative) procedure | No | ||||||||||||||||||||||||||
| Additional remarks genetic modification | The pYCm plasmid based on the CRISPR/Cas9 system was used for genomic editing of the P. berghei ANKA parasite. To generate the pYCm-PbIMC1g-HA (PbIMC1g protein C-terminal tagging) and pYCm-PbIMC1g-HA-DDD (PbIMC1g conditional knockout) vectors for tagging pbimc1g gene with 3?ha or 3?ha-ddd tags, respectively, we first amplified the C-terminal region (60 to 891 bp) of the coding region as the left arm and 1 to 778 bp from the 3?UTR region following the translation stop codon as the right arm using the primers listed in Table S2. The left and right arms were fused by overlapping PCR, with primers bearing the NcoI/SacII sites and 20 bp overlapping sequences necessary for the In-Fusion cloning system (Clontech, CA, USA). They were introduced using HindIII and AflII restriction sites into the pYCm vector. The DNA fragment encoding the 3?HA or 3?HA-DDD tags was inserted into NcoI/SacII sites between the left and right arms in-frame with the gene of interest, respectively. The sgRNA was designed to target the site close to the C-terminal coding region of the pbimc1g gene using the online program EuPaGDT (http://grna.ctegd.uga.edu/). Oligonucleotides for guide RNAs (sgRNAs) were mixed in pairs, denatured at 95?C for 3 min, annealed at room temperature for 5 min, and ligated into the BsmBI site of the bypass plasmid to generate the final plasmids, pYCm-PbIMC1g-HA and pYCm-PbIMC1g-HA-DDD. To generate the pYCm-PbIMC1g-Nmut plasmid for mutating the endogenous predicted N-terminal palmitoylation sites (cysteine 2, 10, and 11) to alanine, we amplified the homologous recombination region (?901 to 661 bp) containing the alanine mutations by overlapping PCR using primers listed in the Table S2 and ligated into the HindIII/AflII of the pYCm plasmid to generate the bypass plasmid. The specific sgRNA that targets the site close to the N-terminal coding region of the pbimc1g gene was designed and ligated into the bypass plasmid as described above to generate the final plasmid, pYCm-PbIMC1g-Nmut. To create the pYCm-PvIMC1g-2?Myc plasmid for replacement of endogenous pbimc1g coding sequence with pvimc1g (PlasmoDB ID: PVX_079955) coding region, we first PCR amplified ?901 to 25 bp of the 5?UTR region as left arm and 29 to 661 bp of the 3?UTR region as right arm using the primers listed in the Table S2. The overlapping PCR was performed using PCR products from 5? and 3? recombination regions to generate the final homologous region that bore the NcoI and SacII sites and ligated into the HindIII/AflII of the pYCm plasmid to generate the bypass plasmid. DNA fragment encoding the entire coding region of pvimc1g was amplified with specific primers and ligated into restriction enzyme sites NcoI/SacII of the bypass plasmid. The specific sgRNA that targets the site close to the N-terminal coding region of the pbimc1g gene was designed and ligated into the bypass plasmid as described above to generate the final plasmid, pYCm-PvIMC1g-2?Myc. The pLyn-FRB-mCherry-nmd3-BSD plasmid was used to generate PbIMC1g deletion and palmitoylation site mutation constructs. Briefly, the endogenous promoter of pbimc1g (?1999 to ?1 bp) was amplified from P. berghei gDNA using primers PbIMC1gpro-BglII-F and PbIMC1gpro-XhoI-R and inserted with BglII/XhoI upstream of the coding sequence. The human DHFR coding sequence was amplified from pSLI-2?FKBP GFP plasmid (95) with primers pLyn-WR-BamHI-F/pLyn-WR-HindIII-R and ligated into BamHI/HindIII sites, resulting in pLyn-FRB-mCherry-WR plasmid. Then, the P. berghei genomic DNA (gDNA) was used as the template to amplify truncations from the pbimc1g coding region, using primers listed in the Table S2. Each insert was cloned into the XhoI and MluI sites of the pLyn-FRB-mCherry-WR plasmid. Transfected parasites were immediately intravenously injected into a na?ve mouse and were either exposed to 0.07 mg/mL pyrimethamine (Sigma) alone or pyrimethamine and 1 mg/mL trimethoprim (TMP; Sigma) 1 day after infection. | ||||||||||||||||||||||||||
| Additional remarks selection procedure | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||
| top of page | |||||||||||||||||||||||||||